Annals of Oncology **4**: 899–908, 1993.

Index of subjects Volume 4 (1993)

A

acquired immune deficiency syndrome
  and HD 621, 635
adenocarcinomas of unknown origin
  phase II study of oral etoposide 789
adenoid cystic carcinoma
  phase II of epirubicin in the treatment of 785
adhesion molecules
  cellular recognition mechanism 545
adjuvant therapy
  for breast cancer 295
  for colorectal cancer S2: 21
adriamycin (see doxorubicin)
adverse drug reactions
  of taxotere, preventive treatment 610
  ophthalmic complications with carboplatin 337
  unexpected fatal toxicity with low dose leucovorin/5-FU 174
  with tamoxifen 683
AIDS
  and Hodgkin's disease 621, 635
ALL (see also leukemia)
  role of ABMT in adults S1: 81
allergic reactions
  to taxotere, preventive treatment 610
alpha-interferon (see interferons)
alternative therapies
  and quality-of-life in cancer patients 121
AML (see also leukemia)
  increased incidence of childhood acute promyelocytic leukemia in Nicaragua 892
  relapse presenting as bone chloroma 339
  role of ABMT S1: 59
  secondary forms after etoposide treatment 559
anemia
  treatment with erythropoietin in tumors 161
aneuploidy fraction
  and DNA index as prognostic factors in breast cancer 643
  role of ploidy in ovarian carcinoma S4: 3
anthracyclines
  epirubicin and ifosfamide in soft tissue sarcomas 669
  epirubicin in adenoid cystic carcinoma 785
  epirubicin in breast cancer 45
  epirubicin ten years later 359
  epirubicin vs. doxorubicin 359
  in continuous infusion 723
  increased dose-intensity in breast cancer 351
anti-emetic therapy
  the state-of-the-art 443, 794
anti-emetic(s)
  current issues in their management S3: 3
  early trial of MDL 73.147 EF: a new 5-HT_3-receptors antagonist 481
  oral ondansetron in patients treated with CMF 475
  pharmacology of tropisetron S3: 15
  review of experiences with ondansetron and granisetron S3: 9
  role of tropisetron S3: 1
  should 5-HT_3 antagonists be first line therapy? 433, 434
  state-of-the-art 443, 793
anticancer drugs
  and biochemical modulation 277
  and relevance of pharmacokinetics 463, 465, 466
  based on DNA topoisomerases as target 533
  p53 as a target of 623
  role of dose intensity 349, 351, 377
  taxotere in experimental ovarian cancer 321
  ten years later: epirubicin 359
antifolate
  edatrexate in melanoma 254
  modulation with leucovorin stereoisomers S2: 1
astrocytoma (see glioma)
autologous bone marrow transplantation
  comparison with conventional salvage treatment in Hodgkin's disease 385
  gonadal function after 399
  in aggressive lymphoma S1: 7
  in breast cancer 351
  in Hodgkin's disease 767, 889
  in low-grade lymphoma S1: 1
  in relapsed Hodgkin's disease 889, S1: 21
  in solid tumors S1: 29
  in solid tumors of childhood S1: 45
  in the primary treatment of Hodgkin's disease S1: 15
  in the treatment of ALL S1: 81
  in the treatment of AML S1: 59

B

bcl-2
  clinical relevance 51
  rearrangement 51
biochemical modulation
  as a model in solid tumors 277
  5-FU-α-IFN monitored by magnetic resonance 597
  meta-analysis of trials involving 5-FU and leucovorin S2: 15
  of 5-FU by oral uridine 317
  sequential methotrexate, 5-FU and leucovorin vs. 5-FU and leucovorin 235
  with stereoisomers of leucovorin S2: 1, S2: 7, S2: 29
biological response modifiers
  after high-dose cyclophosphamide 759
  and oncogenes 35
  and phase I trials methodology 471
  as a continuous infusion in renal cell cancer 689
  for malignant pleural effusions 141
  in ovarian cancer S4: 71, S4: 83
  in the treatment of non-Hodgkin's lymphoma 182, 205
  intrapleural instillation 141
  modulation of 5-FU monitored by magnetic resonance 597
  urinary-derived P-100 877
  with 5-FU and leucovorin in pancreatic cancer 83
biology
  of breast cancer 643
  of cytokines 35
  of ovarian cancer 775, S4: 3
bladder cancer
  bladder preservation with front-line chemotherapy 147
  chemotherapy in patients with poor performance 241

current management of 325
escalated M-VAC with GM-CSF 403
neoadjuvant chemotherapy in 147
second-line M-VAC 793
treatment with carboplatin and 5-FU 241
treatment with carboplatin-containing regimen 313
bleomycin
in follicular lymphoma 205
bone resorption
and tamoxifen 683
bowel obstruction
management of 15
percutaneous gastrostomy in 15
brain metastases
in small-cell lung cancer treated with chemotherapy only 579
breast cancer
adjuvant chemohormonal therapy 295
and biologic prognostic factors 643
and diet in Russia 495
breast-conserving surgery, underutilization 96, 133
CA 153, 807, 861
CAF with or without medroxyprogesterone acetate in adjuvant treatment 295
CEA as tumor marker 861
c-erb-B2 as prognostic factors in advanced breast cancer 585, 807
changing concepts in follow-up 199
combination of doxifluridine, prednimustine and idarubicin 423
dose-intensity 351
drug resistance in 45
endocrine therapy for 712, 735, 741
epidemiology of 41
epirubicin in the treatment of 45, 359, 791
5-FU and folinic acid in the treatment of advanced cases S2: 41
follow-up 199
high-dose FEC in the treatment of 791
incidence and mammography 9, 41
MDR in 11, 45
mitoxantrone, 5-FU and leucovorin in the treatment of advanced cases S2: 37
neu-oncogene and prognosis 585, 807
phase II trial of iproplatin or carboplatin in 303
pre-operative chemotherapy with FEC 791
prognostic significance of ploidy 213
prognostic significance of proliferative activity 184, 213
prognostic significance of tumor markers 807
randomised comparison of tamoxifen, megestrol acetate or their combination in advanced cases 712, 741
reversal of MDR in 11
risk factors in 41
routine follow-up in early breast cancer 199
tamoxifen or medroxyprogesterone acetate in the therapy of advanced cases 712, 735
TPA as tumor marker 861
treatment with epirubicin +/- verapamil 45
tumor markers 195, 807, 861
verapamil for MDR in 45
busulfan
renal cancer after treatment 521

C
CA 125
as indicator to treat ovarian cancer 257
monoclonal antibody specific for 307
CA 153
as indicator in breast cancer 195, 807
CAF
with or without MAP in adjuvant breast cancer 295
cancer
and euthanasia 447, 794
and fears 69
and unorthodox therapy 121
cancer care
in developing countries 7, 263, 283
cancer consultation
role of letters and tapes 549
cancer pain
management 187, 267
cancer research
role of psychoneuroimmunology 714, 745
CAPE/PALE
as salvage treatment in Hodgkin's disease 857
carboplatin
and etoposide in good-risk germ cell tumors 663
and etoposide in ovarian cancer 697
and etoposide in small-cell lung cancer 825
and 5 FU in bladder cancer 245
combinations in ovarian cancer S4: 41, S4: 83
containing regimen for bladder cancer 313
ophthalmic toxicity of 337
phase II study in breast cancer 303
with cisplatin and ifosfamide in cervical cancer 485
carcinogenesis
in renal cell cancer 451
cardiac tamponade
in ovarian cancer 896
CEA
as marker in breast cancer 861
CEMP
in non-Hodgkin's lymphoma 172
cervical cancer
chemotherapy with ifosfamide, carboplatin and cisplatin 485
chemoprevention
and nutrition 117
new preventive agents 117
overview of randomised trials 117
chemotherapy
a) combination
alternating combination in advanced gastric cancer 426
CAF with or without medroxyprogesterone acetate in adjuvant breast cancer 295
CAPE-PALE as salvage treatment 857
CAPE-PALE as salvage treatment in Hodgkin's disease 857
Carbo-MVE for bladder cancer 313
carboplatin and 5-FU in bladder cancer 241
carboplatin, cisplatin and ifosfamide in cervical cancer 485
carboplatin combinations in ovarian cancer S4: 41, S4: 83
carboplatin-etoposide in good-risk germ cell tumors 663
carboplatin in breast cancer 303
carboplatin vs. cisplatin in ovarian cancer S4: 41
CEMP in non-Hodgkin's lymphomas 172

CHOP-Bleo and interferon in follicular lymphoma 205
cisplatin and 120-hour 5-FU in pancreatic cancer 333
cisplatin and etoposide in good-risk germ cell tumors 663
cisplatin combinations in ovarian carcinoma S4: 41, S4: 83
CMV in bladder cancer 147
cyclophosphamide and glutathione in ovarian cancer 55
doxifluridine, prednimustine and idarubicin in breast cancer 423
E-SHAP in non-Hodgkin's lymphomas 63, 896
etoposide and carboplatin in ovarian cancer 697
FEC with dose-intensive epirubicin in breast cancer 791
FEMTX-P in gastric cancer 426
5-FU and folinic acid in breast cancer S2: 41
5-FU and folinic acid in head and neck cancer S2: 45
5-FU combined with [6S]-stereoisomer of folinic acid in colorectal cancer S2: 29
5-FU, epidoxorubicin and cisplatin in gastric cancer 753
5-fU, leucovorin and interferon in pancreatic cancer 83
5-FU with tauromustine and leucovorin in colorectal cancer 81
M-VAC as second line in bladder cancer 793
M-VAC escalated with GM-CSF in bladder cancer 403
mitoxantrone, 5-FU and leucovorin in breast cancer S2: 37
sequential methotrexate, 5-FU and leucovorin 235
suramin and mitomycin-c in prostatic cancer 567
b) single agents
carboplatin, phase II study in breast cancer 303
carboplatin vs. cisplatin in ovarian cancer S4: 41
cisplatin: biweekly administration 221
cisplatin in bladder cancer 147
cyclophosphamide in non-Hodgkin's lymphomas 172
DuP 937 in malignant melanoma 695
DuP 937 in non-small cell lung cancer 693
edatrexate in melanoma 254
epirubicin and ifosfamide in soft tissue sarcomas 669
epirubicin in adenoid cystic carcinoma 785
epirubicin in breast cancer 45
epirubicin ten years later 359
etoposide in non-Hodgkin's lymphomas 63, 172
etoposide oral in adenocarcinomas of unknown origin 789
fludarabine in low-grade non-Hodgkin's lymphomas 575
fludarabine in refractory CLL 371
gemcitabine in renal cell cancer 331
gemcitabine: in vivo activity in xenografts 157
iproplatin, phase II study in breast cancer 303
methotrexate in bladder cancer 147
mitoxantrone in non-Hodgkin's lymphomas 172
oral etoposide in ovarian cancer 517
oral etoposide in small-cell lung cancer 553
taxol in human ovarian carcinoma in nude mice 151
topotecan: Phase I 673
vinblastine in bladder cancer 147
c) general
and dose-intensity 349, 351, 377
and p53 623
biochemical modulation 277, 317
brain metastases treated with chemotherapy only 579
chemo-radiotherapy 94, 125, 256, 802, 804, 831, 847
combination with radiotherapy in the treatment of non-small-cell lung cancer 804, 847
combination with suramin in prostatic cancer 567
concomitant radiotherapy and chemotherapy for gliomas 591
continuous infusions in cancer treatment 723
escalation of dose with GM-CSF 403
for high grade soft tissue sarcoma 509
gonadal function after intensive chemotherapy 399
immunosuppression after purine analogues 347, 371
in hepatocellular carcinoma 489
in Hodgkin's disesae by HIV infection 621, 635
in the treatment of adenoid cystic carcinoma 785
in the treatment of gastrointestinal lymphomas 802, 831, 839
in the treatment of malignant fibrous histiocytoma of bone 409
in the treatment of non-small-cell lung cancer 804
in the treatment of thymomas 429
LNH-87 protocol 651
long-term results in ovarian cancer S4: 35
myocardial infarction after chemotherapy 432
new drugs based on topoisomerases 533
of gallbladder carcinoma 607
ophthalmic toxicity with carboplatin 337
oral combination in breast cancer 423
oral treatment: its role in small-cell lung cancer 529
randomised dose intensity study in ovarian carcinoma 377
results in bladder cancer 325
results in Hodgkin's disesae 385, 417
role of chemotherapy in the treatment of ovarian cancer S4: 83
role of pharmacology 463, 465, 466
salvage treatment in Hodgkin's disease 657, 857
stereoisomers of leucovorin S2: 7
taxol in human ovarian carcinomas growing in the peritoneal cavity of nude mice 151
toxicity of taxotere 610
treatment of soft tisue sarcomas 669
tumor markers as targets for new drugs 195
children
ABMT in solid tumors S1: 45
tropisetron in the control of nausea in S3: 35
chloroma
as presenting relapse by AML 339
chromosome abnormalities
in secondary haematological malignancies after etoposide 559
in solid tumors 821
cisplatin
and 5-FU in 120-hour infusion in pancreatic cancer 333
and etoposide in good-risk germ cell tumors 663
and etoposide in the treatment of brain metastases 579
as a continuous infusion 723
combinations in ovarian cancer S4: 41, S4: 83
cyclophosphamide and glutathione in ovarian cancer 55
high-dose in ovarian cancer 55, S4: 41
its use in an anephric patient 679
treatment of non-Hodgkin's lymphomas 63
vs. carboplatin in ovarian cancer S4: 41
with carboplatin and ifosfamide in cervical cancer 485
with 5-FU, folinic acid and epidoxorubicin in gastric cancer 753
clinical cases
bladder cancer 325
fever and neutropenia 603
high grade soft tissue sarcoma 509
Hodgkin's disease 417
mediastinal mass 781
ovarian cancer 883
tamoxifen and hypercalcaemia 683
CLL
antitumor activity and immunosuppression of purine analogues 347

results with fludarabine in refractory cases 371
clodronate
its use with tamoxifen 683
severe hypocalcaemia after 432
clonal excess
prognostic relevance of non-Hodgkin's lymphomas 393
colony stimulating factor
escalated M-VAC with GM-CSF in bladder cancer 403
colorectal cancer
chemotherapy of 81
5-FU and interferon 515
5-FU combined with [6S]-stereoisomer of folinic acid in the treatment of S2: 29
5-FU with tauromustine in the treatment of 81
meta-analysis of trials with leucovorin S2: 15
randomized comparison of 5-FU, leucovorin +/- methotrexate 235
trial for adjuvant treatment in high-risk colorectal cancer S2: 21
unexpected fatal toxicity with 5-FU and leucovorin 174
combined modality
in the treatment of gastrointestinal lymphomas 802, 831, 839
in the treatment of gliomas 591
in the treatment of non-small-cell lung cancer 804, 847
in the treatment of ovarian cancer S4: 23, S4: 31, S4: 35, S4: 83
complementary therapy
vs. unorthodox cancer therapy 121
continuous infusion
an appraisal of 5-FU, doxorubicin and platinums 723
120-hour infusion of 5-FU in pancreatic cancer 333
cross-resistance
and dose-relationship in breast cancer 351
between epirubicin and doxorubicin 359
cisplatin vs. carboplatin S4: 41
cyclophosphamide
and inefficient drug metabolism 895
in non-Hogdkin's lymphoma 172
with cisplatin and glutathione in ovarian cancer 55
cyproterone acetate
and hepatotoxicity 701
cytogenetics
and carcinogenesis in renal cell cancer 451
in secondary haematological malignancies after etoposide 559
in solid tumors 821
cytokines
and oncogenes 35
in ovarian cancer S4: 71, S4: 83

D

debulking surgery
and its role in ovarian cancer 264, 289, S4: 17, S4: 23, S4: 31, S4: 83
DEL 6q
in diffuse lymphomas 51
dexamethasone
and tropisetron in the control of nausea and vomiting S3: 31
diet
content of fat and breast cancer risk in Russia 495
differentiation
of small cell lung cancer cell lines by different agents 499
DNA
aneuploidy 75
prognostic significance of ploidy in breast cancer 213
role of ploidy in ovarian carcinoma S4: 3
docetaxel (see taxotere)
dose intensity
a review of concepts 23
and dose calculation 103
combined retrospective analysis of studies 103
correlation with drug selection and scheduling 103
correlation with outcome 23
in breast cancer 351
in ovarian cancer 349, S4: 31, S4: 35, S4: 49, S4: 57, S4: 83
increase through biweekly cisplatin administration 221
its prognostic significance in non-Hodgkin's lymphomas 651
prospective studies 103
doxifluridine
with idarubicin and prednimustine in breast cancer 423
doxorubicin
in continuous infusion 723
vs. epirubicin 359
drug discovery
tumor markers as targets 195
drug resistance
in breast cancer 9, 45
in ovarian cancer S4: 57
DuP (see teloxantrone)

E

E-SHAP
for refractory and relapsing lymphoma 63, 896
edatrexate
in melanoma: phase II 254
emotional distress
and low natural cytotoxic activity 714, 745
endocrine therapy
with CAF in breast cancer 295
with tamoxifen, megestrol acetate, or their combination in advanced breast cancer 712, 741
with tamoxifen or medroxyprogesterone acetate in breast cancer 712, 735
epidemiology
breast cancer risk and diet in Russia 495
epirubicin
and cardiotoxicity 359
and ifosfamide in soft tissue sarcomas 669
in adenoid cystic carcinoma 785
ten years later 359
with 5-FU, folinic acid and cisplatin in gastric cancer 753
with verapamil in breast cancer 9, 45
erbB2
amplification in ovarian cancer 775
erythropoietin
treatment of chronic anemia in tumors 161
ESMO
recognition of medical oncology 101
survey of members 101
etiology
of ovarian cancer S4: 3
etoposide
and carboplatin in ovarian cancer 697
and carboplatin in small-cell lung cancer 825
and cisplatin in the treatment of brain metastases 579
and secondary haematological malignancies 559
in the treatment of adenocarcinomas of unknown primary site

789
low-dose oral in ovarian cancer 517
prolonged oral administration in small-cell lung cancer 529, 553
treatment of non-Hodgkin's lymphomas 63
with cisplatin or carboplatin in good-risk germ cell tumors 663
euthanasia
a comment 794
a professional point of view 794
in The Netherlands: fact and moral arguments 447

F
FEC
high-dose in breast cancer 791
FEMTX-P
in gastric cancer 426
fever
and neutropenia: management 603
fibronectin
as adhesion molecule 545
flow cytometry
and its use in breast cancer as prognostic factor 643
and its use in non-Hodgkin's lymphomas 393
fludarabine
immunosuppression with 347
in CLL 371
in treatment of low-grade non-Hodgkin's lymphomas 575
fluoropyrimidines
modulation with leucovorin 277
scheduling of major representatives 277
fluorouracil
and interferon in colorectal cancer 515
combined with folinic acid in advanced breast cancer S2: 41
combined with folinic acid in the treatment of head and neck cancer S2: 45
combined with mitoxantrone and leucovorin in breast cancer S2: 37
combined with [6S]-stereoisomer of folinic acid in colorectal cancer S2: 29
in continuous infusion 723
in the treatment of malignant gliomas 591
meta-analysis of trials with leucovorin S2: 15
monitoring of modulation by α-IFN using magnetic resonance 597
reversal of toxicity by oral uridine 317
sequential combination with methotrexate +/- leucovorin in colorectal cancer 235
trials in high-risk resected colorectal cancers S2: 21
unexpected fatal toxicity with low-dose leucovorin 174
with folinic acid, epidoxorubicin and cisplatin in gastrc cancer 753
with leucovorin and interferon in pancreatic cancer 83
with tauromustine and leucovorin in colorectal cancer 81
folinic acid (see also leucovorin)
and interferon in colorectal cancer 515
meta-analysis of trials with leucovorin S2: 15
with 5-FU, epidoxorubicin and cisplatin in gastric cancer 753
with 5-FU in breast cancer S2: 4, S2: 37
with 5-FU in head-neck S2: 45
follicular lymphomas (see lymphomas and non-Hogdkin's lymphomas)

G
gallbladder cancer
phase II trial of mitomycin-c 607
gastric cancer
after lymphoma 256
high-dose MTX and 5-FU alternated with epirubicin and cisplatin 426
treatment with FLEP combination chemotherapy 753
gastrointestinal lymphoma
an unresolved question 802
combined modality for the treatment of 831
treatment of primary gastric lymphoma 839
gemcitabine
in renal cell cancer 331
in xenografts 157
germ cell tumors
cisplatin-etoposide and carboplatin-etoposide in the treatment of 663
treatment for good-risk patients 663
glioma
chemotherapy and concomitant radiotherapy 591
glutathione
and cyclophosphamide in ovarian cancer 55
GM-CSF
and escalted M-VAC in bladder cancer 403
granisetron
review of the experience with S3: 9
growth factors (see also biological response modifiers)
and phase I trials methodology 471
urinary-derived P-100 877

H
head and neck cancer
5-FU and folinic acid in the treatment of S2: 45
psychosocial problems 69
treatment with epirubicin of adenoid cystic carcinoma 785
hematopoietic recovery
with IL-3 after high-dose cyclophosphamide 759
hematopoietic support
in ovarian cancer S4: 49, S4: 57, S4: 83
hepatitis C
late seroconversion in hematologic disorders 229
hepatocelluar carcinoma
prognostic factors in patients with 489
hepatotoxicity
in the treatment with cyproterone acetate 701
high-dose chemotherapy
and biweekly cisplatin administration 221
and its use in breast cancer 351
hematopoietic recovery after IL-3 759
in aggressive lymphoma S1: 7
in breast cancer 23
in low-grade lymphoma S1: 1
in ovarian cancer S4: 49, S4: 57, S4: 83
in relapsed Hodgkin's disease S1: 21
in solid tumors S1: 29
in solid tumors of childhood S1: 45
in the primary treatment of Hodgkin's disease S1: 15
in the treatment of ALL S1: 81
in the treatment of AML S1: 59
MTX and 5-FU alternated with epirubicin and cisplatin in

gastric cancer 426
review of concepts 23
with FEC in breast cancer 791
with hematopoietic rescue in Hodgkin's disease 767
histiocytoma
chemotherapy of malignant fibrous histiocytoma of bone 409
HIV
and Hodgkin's disease 621, 635
Hodgkin's disease
and its current management 417
and prognostic factors 385
and second malignancies 94, 125
and secondary cancer 520
chemotherapy in HIV-cases 621, 635
correlation with cell proliferation 75
correlation with DNA aneuploidy 75
current management 417
early relapses 857
high-dose chemotherapy with hematopoietic rescue 767, 889
high-dose sequential chemo-radiotherapy 889
in HIV infection 621, 635
in i.v.-drug users 621, 635
late relapses 657
long term results 385
prognosis of 75
prognostic factors after high-dose chemotherapy 767
role of ABMT in primary cases S1: 15
role of ABMT in relapsed cases S1: 21
role of progenitor cell support in relapsed cases 889
salvage therapy 385, 857
salvage treatment 889
salvage treatment in early disease 857
salvage treatment in late relapses 657, 857
second malignancies, after ABVD chemotherapy 94
second malignancies, after MOPP chemotherapy 94
second malignancies, correlation with age 125
second malignancies, correlation with treatment intensity 125
hypercalcaemia
under tamoxifen 683

I
idarubicin
with prednimustine and doxifluridine in breast cancer 423
ifosfamide
and epirubicin in soft tissue sarcomas 669
with carboplatin and cisplatin in cervical cancer 485
IL-2
as a continuous infusion in renal cell cancer 689
IL-3
after high-dose cyclophosphamide 759
immunosuppression
after treatment with fludarabine 371
after treatment with purine analogues 347, 371
and seroconversion of hepatitis C virus 229
infections
after fludarabine for low-grade lymphoma 575
after treatment with fludarabine in CLL 371
in immunosuppression due to purine analogues 347
integrin
as adhesion molecule 545
interferon(s)
and folinic acid in colorectal cancer 515
for malignant pleural effusions 141
in the treatment of non-Hodgkin's lymphoma 182, 205
intrapleural instillation 141
modulation of 5-FU monitored by magnetic resonance 597
with 5-FU and leucovorin in pancreatic cancer 83
intrapleural therapy
instillation with interferon 141
iproplatin
phase II study in breast cancer 303
Italy
teaching of clinical oncology 717

L
leucovorin
and interferon in colorectal cancer 515
combined with5-FU in advanced breast cancer S2: 41
combined with 5-FU in the treatment of head and neck cancer S2: 45
combined with mitoxantrone and 5-FU in breast cancer S2: 37
different isomers 277
meta-analysis of trials with 5-FU S2: 15
pharmacokinetics of stereoisomers S2: 1
role of different stereoisomers S2: 7
unexpected fatal toxicity in combination with 5-FU 174
with 5-FU and interferon in pancreatic cancer 83
with 5-FU and tauromustine in colorectal cancer 81
leukemia
acute promyelocytic variant in Nicaragua 892
dose intensity 23
general management of 631
new research questions 631
liver cirrhosis
and hepatitis C in haematologic disorders 229
and malignant lymphoproliferative disorders 245
lung cancer
activity of gemcitabine in xenografts treated with gemcitabine 157
brain metastases from small-cell lung cancer treated with chemotherapy only 579
carboplatin and etoposide 877
combined treatment with chemo-radiotherapy for NSCLC 804, 847
differentiation of small cell lines by different agents 499
dose intensity 23
DUP 937 in NSCLC 693
in HIV patients 85
non-small cell, phase II of DuP 937 693
P-100 derived growth factor in the treatment of 877
role of oral etoposide in the treatment of small-cell lung cancer 529, 553
lymphoma(s) (see also non-Hodgkin's lymphomas)
and liver cirrhosis 245
CEMP in the treatment of 172
cytogenetics 51, 825
etoposide in the treatment of 63
fludarabine in the treatment of 575
follicular lymphoma 182, 825
gastrointestinal lymphoma 802, 831, 839
immunoblastic and BCL-2 rearrangement 51
large cell and BCL-2 rearrangement 51
prognostic index in high grade 853
role of E-SHAP in refractory cases 63, 896
role of interferon 182
transformation in low-grade lymphomas 825

treatment with CHOP-Bleo and interferon 205
lymphoproliferative diseases
and multistep tumorigenesis 825
MLDUS 825

M

M-VAC
as second line in patients previously treated with the same regimen 793
escalated with GM-CSF in bladder cancer 403
MACOP-B
and gonadal function in patients with non-Hodgkin's lymphoma 399
magnetic resonance
intratumoral pharmacokinetic of gemcitabine in xenografts 157
monitoring biochemical modulation of 5-FU and α-IFN 597
MALT lymphoma
and follicular lymphoma 182
in the gastrointestinal tract 802, 831, 839
mammography
and overdiagnosis of breast cancer 9
cancer detection by 41
MDR
and p-glycoprotein 11
mechanism of action
carcinogenesis 451
of adhesion molecules 545
of p-glycoprotein 11
p53 as a target for anticancer drugs 623
topoisomerases 533
mediastinal mass
current management 781
medical oncology
teaching of, in Italy 717
medroxyprogesterone acetate (MAP)
combined with CAF in adjuvant breast cancer 295
or tamoxifen in advanced breast cancer 712, 735
megestrol acetate
or tamoxifen or their combination in advanced breast cancer 712, 741
melanoma
human antigen 35
phase II of DuP 937, 695
phase II study of edatrexate 254
meta-analysis
in ovarian cancer S4: 23, S4: 79
of 5-FU and leucovorin S2: 15
metabolism
of cyclophosphamide and bone marrow toxicity 895
methotrexate
in bladder cancer 147
modulation with leucovorin stereoisomers S2: 1
sequential with 5-FU and leucovorin 235
mitomycin-c
combined with suramin in prostatic cancer 567
phase II in gallbladder 607
mitoxantrone
combined with 5-FU and leucovorin in breast cancer S2: 37
in lymphomas 172
molecular biology
and adhesion molecules 545
and cytogenetics in solid tumors 821
of transformation in low-grade lymphomas 825
rearrangement of bcl-2 51
topoisomerases as target for new anticancer drugs 533
monoclonal antibodies
In-111-labeled specific for CA125 307
myeloma
dose intensity 23
myocardial infarction
after chemotherapy for testicular teratomas 432
unexpected fatal toxicity with low dose leucovorin/5-FU 174

N

natural killer cells
and emotional distress 714, 745
nausea (see also antiemetics)
current management S3: 3
in children: role of tropisetron S3: 35
prophylaxis of nausea with oral ondansetron 475
role of tropisetron in gynecological patients S3: 47
role of tropisetron in patients resistant to conventional antiemetic therapy S3: 25
tropisetron and dexamethasone in the control of S3: 31
neutropenia
its management during intensive chemotherapy 603
new drugs
and their role in ovarian cancer S4: 63, S4: 79
Nicaragua
acute promyelocytic leukemia in 892
developing oncologic project in 37
non-Hodgkin's lymphomas (see also lymphomas)
chemotherapy in elderly patients 172
fludarabine in treated and untreated patients 575
interferon in the treatment of follicular lymphomas 182, 205
prognostic impact of clonal excess 393
prognostic significance of dose intensity 651
role of ABMT in aggressive cases S1: 7
role of ABMT in low-grade cases S1: 1
salvage chemotherapy 63, 251
nude mice
activity of gemcitabine in small-cell lung cancer 157
antitumor activity of taxotere in ovarian cancer 321
treatment with taxol in ovarian carcinoma 151
nutrition
and breast cancer 495
and chemoprevention 117

O

oncogenes
and chromosome abnormalities in solid tumors 821
and cytokines 35
erbB2 amplification in ovarian cancer 775
role in transformation of low-grade lymphomas 825
role of bcl-2 51
oncology
in developing countries 7, 263, 283
teaching of, in Italy 717
ondansetron
a randomised trial vs. placebo in patients treated with CMF 475
review of the experience with S3: 9
opioid
drugs in cancer pain 267
oral
etoposide 63, 517, 529, 553

three-drugs combination in treatment of breast cancer 423
ovarian carcinoma
activity of taxol in xenografts 151
and surgical procedure 264, 289, S4: 17, S4: 23, S4: 83
antitumor activity of taxotere in cell lines 321
biological role of oncogenes 775, S4: 3
CA125 in S4: 71
carboplatin versus cisplatin S4: 41
cardiac tamponade in 896
consensus statements S4: 83
epidemiological aspects 264, 289
erb-B2 amplification 775
etiology of S4: 3
etoposide and carboplatin in the treatment of 697
immunoscintigraphy for detection of recurrence 307
long term results S4: 35
management of 883
meta-analyses in S4: 79
new drugs in the treatment of S4: 63, S4: 83
overexpression of 185, 775
pathogenesis of S4: 3
prognostic factors S4: 3, S4: 23, S4: 31, S4: 35, S4: 79, S4: 83
randomised dose intensity study 377
results with oral etoposide 517
role of drug resistance S4: 57
second-line treatment in S4: 83
second-look laparotomy 169
survival after cisplatin treatment 264, 289
the impact of dose-intensity 23, 349, 377, S4: 49, S4: 57
tumor markers in S4: 71, S4: 83

P
P-100
as urinary-derived growth factor 825
P-glycoprotein
and MDR 11
p53
as a target for new anticancer drugs 623
p185
overexpression in ovarian cancer 775
pancreatic cancer
chemotherapy 83
phase II of cisplatin and 120-hour 5-FU 333
patient-care
doctors' views on letters and tapes 549
pediatric oncology
in developing countries 37
peripheral stem-cell transplantation (see also progenitor cell support)
after high-dose chemotherapy in Hodgkin's disease 767
pharmacokinetic(s)
and metabolism for high-dose cyclophosphamide 895
dose intensity 23
of biweekly cisplatin administration 221
of cisplatin in an anephric patient 679
of fluoropyrimidines 277
of 5-FU with interferon 515
of leucovorin stereoisomers S2: 1
of opioid drugs in cancer pain 267
of oral etoposide in small-cell lung cancer 553
of topotecan 673
of tropisetron S3: 15
pharmacology of 5-FU, hydroxyurea and iododeoxyuridine 591
the relevance of pharmacology in clinical oncology practice 463, 465, 466
phase I
are hematopoietic growth factors changing the methodology? 471
5-FU and oral uridine 317
of MDL 73.147 EF: a new 5-HT_3-receptors antagonist 481
topotecan 673
phase II
carboplatin in breast cancer 303
cisplatin and 120-hour 5-FU in pancreatic cancer 333
DuP 937 in malignant melanoma 695
DuP 937 in non-small cell lung cancer 693
gemcitabine in renal cell cancer 331
iproplatin in breast cancer 303
of epirubicin in adenoid cystic carcinoma 785
of etoposide in adenocarcinomas of unknown origin 789
of ifosfamide, carboplatin and cisplatin in cervical cancer 485
of mitomycin-c in gallbladder cancer 607
of oral combination of doxifluridine, prednimustine and idarubicin in breast cancer 423
of suramin and mitomycin-c in prostatic cancer 567
oral etoposide in ovarian cancer 517
oral etoposide in small cell lung cancer 553
recombinant IL-2 in renal cell cancer 689
platinum (see carboplatin, cisplatin, iproplatin)
pleural effusions
interferon instillation for the treatment of malignant effusions 141
ploidy
prognostic significance in breast cancer 213
role in ovarian cancer S4: 3
prednimustine
with doxifluridine and idarubicin in breast cancer 423
progenitor cell support
for relapsed Hodgkin's disease 889
prognostic factors
and results with E-SHAP in refractory lymphomas 63, 896
aneuploidy and DNA index in breast cancer 643
dose intensity in non-Hodgkin's lymphoma 651
in bone marrow transplantation for Hogdkin's disease 767
in hepatocellular carcinoma treated with chemotherapy 489
in high grade lymphomas 853
in ovarian cancer S4: 3, S4: 23, S4: 31, S4: 71, S4: 79, S4: 83
neu-oncogene in advanced breast cancer 585
tumor markers in breast cancer 195, 807
prognostic index
in high grade lymphomas 853
proliferative activity
available measurements 184
prognostic significance in breast cancer 213
role in clinical oncology 184
promyelocytic leukemia
increased incidence in childhood in Nicaragua 892
prostate cancer
results with suramine combined with mitomycin-c 567
psycho-oncology
and alternative therapies 121
in familial cancer 714, 745
psycho-social problems in head and neck cancer 69
psycho-neuroimmunology
in familial cancer and emotional distress 714, 745

purine analogues
antitumor activity in CLL 347, 371
in the treatment of lymphomas 393

Q

quality-of-life
and clinical trials 520
and unorthodox cancer therapy 121
influence of the type of surgical treatment for breast cancer 133
in patients with head-and-neck cancers 69

R

racemic form
of leucovorin and its role S2: 1
radiotherapy
and chemotherapy in gastrointestinal lymphomas 802, 831, 839
combined with chemotherapy for malignant gliomas 591
combined with chemotherapy in non-small-cell lung cancer 804, 847
in Hodgkin's disease during HIV infection 635
its role in ovarian cancer S4: 83
randomized trial
CAF with or without MPA in adjuvant breast cancer 295
carboplatin vs. cisplatin in ovarian cancer S4: 41
comparison of 5-FU, leucovorin, +/- methotrexate 235
of different dose intensity in ovarian cancer 377
of endocrine agents in breast cancer 712, 735, 742
iproplatin vs. carboplatin in breast cancer 303
with/without verapamil in breast cancer 45
renal cell cancer
after busulphan treatment 521
and cytogenetics 451
continuous infusion of IL-2 in the treatment of 689
phase II of gemcitabine 331
role of carcinogenesis 451
renal function
cisplatin in anephric patient 679
rhabdomyosarcoma
paratesticular localisation in adults 871

S

S-phase fraction
as prognostic parameter in breast cancer 643
salvage treatment
in Hodgkin's disease with early relapses 857, 889
in Hodgkin's disease with late relapses 657
with etoposide and carboplatin in ovarian cancer 697
sarcoma
chemotherapy of malignant fibrous histiocytoma of bone 409
second cancer
after busulfan treatment 521
after etoposide treatment 559
second-look laparotomy
in the management of ovarian cancer 169
soft tissue sarcomas
current management 509
epirubicin and ifosfamide in the treatment of 669
paratesticular rhabdomyosarcomas in adults 871
solid tumors
role of cytogenetics 821
stereoisomers
current state-of-the art for leucovorin S2: 7
of leucovorin and their pharmacokinetics S2: 1
suramin
combined with mitomycin-c in prostatic cancer 567
surgery
and its role in ovarian cancer 69, 264, 289, 857, S4: 17, S4: 23, S4: 31, S4: 83
breast conserving, underutilization 96, 133

T

tamoxifen
and hypercalcaemia 683
randomised trial vs. medroxyprogesterone acetate in advanced breast cancer 712, 735
vs. megestrol acetate or in combination with megestrol acetate in advanced breast cancer 712, 741
tauromustine
with 5-FU and leucovorin 81
taxol
in ovarian carcinoma in nude mice 151
taxotere
antitumor activity in experimental ovarian cancer 321
preventive treatment of toxicities 610
teaching
of clinical oncology in Italy 717
teloxantrone
phase II trial in malignant melanoma 695
phase II trial in non-small cell lung cancer 693
terminal cancer patients
palliative treatment in 15
with bowel obstruction 15
testicular cancer
cisplatin-etoposide and carboplatin-etoposide in the treatment of 663
myocardial infarction after chemotherapy 432
paratesticular rhabdomyosarcomas in adults 871
treatment for good-risk patients 663
thymomas
results with chemotherapy 429
topoisomerase
as target for new anticancer drugs 533
topotecan, a new topoisomerase I inhibitor 673
topotecan
phase I of 673
toxicity
of tamoxifen 683
of taxotere, preventive treatment 610
ophthalmic complication with carboplatin 337
unexpected fatal toxicity of low-dose leucovorin/5-FU 174
TPA
as tumor marker in breast cancer 861
tropisetron
and its role in antiemetic treatment S3: 1
combined with dexamethasone in the control of vomiting S3: 31
experience with its compassionate use S3: 43
its development S3: 19
its role as antiemetic in children S3: 35
its role in gynecological patients S3: 47
pharmacology and toxicology of S3: 15
role of, in patients resistant to conventional antiemetic therapy S3: 25
the Nordic experience S3: 39

tumor immunology
and cytokines 35
tumor markers
and their role in breast cancer 195, 807
and their role in ovarian cancer S4: 71, S4: 83
CA125 in ovarian cancer 257, S4: 71
CA153 861
CEA in breast cancer 861
TPA in breast cancer 861
tumor suppressor genes
and cytogenetics in solid tumors 821
p53 as a target for new drugs 623
their role in transformation of low-grade lymphomas 825

U
uridine
and its use in reversing 5-FU toxicity 317

V
VACOP-B
gonadal function in patients with non-Hodgkin's lymphomas 399
venous access
migration of implantable infusion catheter 173
verapamil
and MDR 11
with epirubicin in breast cancer 11, 45
vinblastine
in bladder cancer 147
vomiting
current issues in its management S3: 3
role of tropisetron as a new antiemetic S3: 1
role of tropisetron in patients at risk of severe emesis S3: 43
treatment with tropisetron in children S3: 35
treatment with tropisetron in gynecological patients S3: 47
tropisetron and dexamethasone in the treatment of S3: 31
VP-16 (see etoposide)

X
xenografts
activity of gemcitabine in small cell lung cancer 157
antitumor activity of taxotere in ovarian cancer 321
of human ovarian carcinoma treated with taxol 151

Y
Yolk sac tumor
and cardiac tamponade 896

Z
zidovudine
in AIDS and HD 621, 635

Annals of Oncology 4: 909–913, 1993.

Index of authors Volume 4 (1993)

A
Aage Engelholm S 485
Aapro MS 475, 481, S3: 9
Abad A 753
Abbott BJ 151
Adenis A 174
Alberto P 423, 481, 559
Alcaraz A 313
Alerci M 553
Algor R 69
Allen DG S4: 83
Allen PK 125
Alvarez R 313
Amess J 385
Anderson H 393
André T S2: 29
Andreadis CG 896
Andrieu JM 635
Angiolini C 133
Ansell SM 172
Antman KH S1: 29
Antón-Torres A 753
Aparicio Urtasun J 896
Aranda E 753
Arapantoni-Dadiotou P 256
Arcangeli G S2: 41
Arena MG 241
Armand JP 333
Armitage JO 767, S1: 1
Athanassiou A 256
Audisio RA 607
Aversa SML 657

B
Baak J S4: 3, S4: 83
Babaeva M 495
Baez Lacayo F 37
Bagin RG 767
Baines MJ 15
Bajetta E 251, 489
Ballatori E 795
Balzarotti M 831
Barbounis V 385
Barbui T 631
Bardon M S2: 29
Barrada M 697
Basile M 333
Bauer J 475
Baur M 697
Beijnen J 673
Belanger K 695
Belón J 753
Belpomme D S4: 41, S4: 83
Benahmed M 333
Bendandi M 575
Benfenati D 575
Berek JS S4: 3, S4: 71, S4: 83
Berezin F 591
Bergmann L 371
Beris P 559
Berruti A 429
Bertelsen K S4: 35, S4: 49, S4: 83
Bertulli R 831
Bianco A 657
Bidoli P 359
Bierman PJ 767, S1: 1
Biete A 313
Bignami P 489
Biondi A 37, 892
Bishiniotis TS 896
Bishop MR S1: 1
Bissery MC 321
Bisset D 432
Björkholm M 229
Blanco E 753
Bleiberg H 607, S3: 43
Blijham GH 75, 295, 607, 643
Bocchia M 575
Bochicchio AM 489
Bodurtha AJ 254
Bohm S 55
Bohn C 45
Bokemeyer C 520
Bonadonna G 94, 359, 759, 831, 889
Bonetti A 221
Bonfante V 359
Bonfanti G 489
Boni L 489
Bonneterre J 174
Boracchi P 213
Borasio P 429
Bosly A 651, S1: 7
Bourguet P 307
Bovbjerg DH 745
Boven E 321
Boyce M 481
Boyle P 495
Bozzetti F 831
Brachman D 591
Braly P 221
Breed WP 75
Bregni M 759, 889
Brice P 635
Bron H 295
Brown BW 125
Brown R 623
Brunner KW 475, 735
Bruntsch U S3: 25
Bruzzi P 41
Bucchi L 41
Buckley CH 377
Buonadonna A 669
Burgers JMV 839
Burghouts JTh 426
Burns I 741
Busch B 481
Buser KS 475
Butcher M 475
Butow PN 549
Buyse M S2: 15
Buzzoni R 251, 489
Byrne M 741

C
Cabanillas FF 51, 125, 205
Cabrol C 559
Calabresi F 241
Calvert AH S4: 83
Campiglio M 775
Camplejohn R 184
Camps C 753
Cancrini A 241, 689
Cantù Rajnoldi A 892
Carbone A 669
Carella AM S1: 15
Carloni G 701
Carpano S 689
Casali P 359
Cascinu S 83
Castiglione-Gertsch M 735
Catalano G 83
Catimel G 471
Cattabeni M 775
Cavalli F 6, 37, 99, 263, 475, 517, 553, 735, 794, 892
Cavallin-Ståhl E 393
Celio L 489
Cellerino R 717
Cervantes A 753
Chabot GG 679
Chaitchik S 69
Charette J 591
Chatal J-F 307
Chiarion Sileni V 657
Clavel M 303, 471, 785
Coates A 741
Cognetti F 785
Coiffier B 182, 651, S1: iv, S1: 7
Colleoni M 251, 489
Collins DJ 597
Colombo N 517, 775, S4: 49
Conroy Th 426
Conte PF S4: 41, S4: 83
Conter V 37, 892
Corgna E 847
Cortes-Funes H 147
Costas P 147
Crinò L 701, 847
Crivellari D 669
Crosato I 85
Crowther D 377, 417
Culine S 793, 871
Cummings J 533
Cunningham D 597

Cvitkovic E 333

D
D'Incalci M 151, 517, 553, 775, 895
Dadiotis L 385
Daidone MG 213
Dal Cin P 821
Dalgleish A 433
Daniels M 313
Darwish S 847
Daugaard G 683
Dauplat J S4: 49, S4: 57, S4: 83
Davidson J 254
de Boer-Dennert M 673
de Braud F 251
de Bruijn KM S3: 19, S3: 25, S3: 31, S3: 47
de Graeff A 426
de Jong J 295, 553
de Mulder PHM 403, 785
de Vries EGE S4: 57, S4: 83
de Wet M 567
De Carli P 241
De Conno F 15, 187, 267
De La Pierre M 245
De Palma CA 251
De Paoli A 669
De Wasch G S3: 43
Degardin M 174
Del Bino G 213
Del Favero A 795
Del Medico P 689
DelaFlor-Weiss E 723
Demicheli R 359
Desablens B 635
Di Fronzo G 213
Di Lauro L 689
Di Nicola M 759, 889
Di Re F 55
Diaz-Puente M 147
Díaz-Rubio E 753
Dicke KA 767, S1: 59, S1: 81
Dimitriades M 256
Dirix LY 610, 883, S3: 43
Dittrich C 697
Dodion P 303
Dodwell D 23, 103
Dogliotti L 429
Dohrmann GJ 591
Dolan ME 591
Dombernowsky P 861
Dorta J 753
Dougal M 377
Drechsler S S3: 25
Droz J-P 333, 679, 793, 871
Duchesne GM 325
Ducreux M 333
Duez N 607
Dupuis HM 447
Dutin, J-P 307

E
Earl HM 409, 877
Edler L 45
Eisenhauer EA 254, 331, 693, 695, S4: 35, S4: 41, S4: 63, S4: 83
Erdkamp FL 75
Erkelens CAM 321
Errante D 85
Estapé J 313
Evans TRJ 433
Evstifeeva T 495

F
Fairey AF 857
Falkson G 172, 567
Fanin R 575
Favalli G S4: 41, S4: 83
Fazeny B 697
Fedeli A 83
Fenchel K 371
Ferreri AJM 831
Fey MF 339
Fickers M 295, 426
Filtenborg TA 485
Findlay MPN 597
Fine S 693
Fiorentino MV 657
Fisher B 96
Fisken J 257
Foa P 521
Foladore S 669
Fonseca E 753
Fossa SD 403
Franceschi S 41, 289
Freshney RI 499
Freund M 520
Fritz E 161
Frustaci S 669
Fuller LM 125
Fumoleau P 307

G
Gale RP S1: 81
Galieni P 575
Gandola L 889
Ganesan TS 385, 703
García-Conde J 753
García de Peredes M 753
Garin AM 663
Gastaut JA 635
Gebbers J-O 781
Gebski V 741
Gelmon K 693
Gencik M 825
Gennari L 489
Gentili D 553
Gershanovich M S3: 35
Ghetti V 717
Giannarelli D 403
Gianni AM 759, 889
Gianni L 359, 463
Giardini R 831
Giavazzi R 151
Gill PG 741
Gisselbrecht C 651, S1: 7
Glaholm J 597
Glimelius B 235
Gloor E 289
Gnant MFX 643
Goebel M 45
Goel R 221
Goldhirsch A 735
Goldman CA 141
Goldschmidt E S2: 29
Goldstone AH S1: 21
Gómez Codina J 896
Goodacre A 51
Gorbunova VA 663
Gorin NC S1: 59, S1: 81
Gorzegno G 429
Gouyette A 679
Gozzetti A 575
Gralla RJ S3: 3
Graziano F 717
Gregg RWC 693
Gregory W 385
Grilli R 133
Grillner L 229
Grison X S2: 29
Gruber A 229
Guaraldi M S2: 45
Guillot T S2: 29
Gundersen S 303
Gurney H 23, 103
Gutterman JU 205

H
Hacker NF S4: 17, S4: 35, S4: 83
Haefliger JM 475
Hagemeister FB 125, 205
Hainsworth JD S2: 37
Haioun C 651, S1: 7
Hamilton JM 663
Hamilton TC S4: 3, S4: 57, S4: 83
Handberg J 173
Hannoun L S2: 29
Hansen HH 157, 485, 579, 673, S4: 63, S4: 83
Hansen M 169, S4: 63, S4: 83
Hansen SW 173
Harland SJ 325
Hart AAM 839
Hartley JM 895
Hartman O S1: 45
Hayes DF 807
Heidemann E 45
Heintz APM S4: 23
Hekmatpanah J 591
Hemler ME 545
Henzen-Logmans SC 789
Herbrecht R 651
Hérry J-Y 307
Himmelmann A S3: 31
Hoelzer DF 371, S1: 81
Höffken K 585
Hoffmann JJ 75
Högberg T S3: 31
Horner D 174

Hossfeld DK 45
Howell SB 221
Hudec M 697
Hülskamp F 585
Hupperets PSGJ 295
Hürny C 520

I
Iscoe NA 254
Iurlo A 521
Izrael V S2: 29

J
Jagannath S 767
Jager J 295
Jahn B 371
Jakesz R 643
Janssen WC 75
Joel SP 529
Johnson A 393
Johnson PWM 63
Jonat W 45
Jones AE 385, 877
Jones HW 857
Joss RA 434, 475, 781, S3: 1
Jotterand Bellomo M 559
Jungi WF 475

K
Kaern J S4: 3
Kahn MZ 499
Kaizer L 693
Kappen HJ S4: 31
Kath R 585
Kattan J 793, 871
Kaye SB 303, 432, 443, 610, 795, S4: 41, S4: 79, S4: 83
Keating MJ 347
Kemp H 409
Kessinger A 767
Kim S 221
Kirchner V 481
Kirkpatrick A 785
Kirmani S 221
Klastersky J 603
Koier I 673
Kolygin B S3: 35
Kolyszko Tuxen M 169
Krainer M 161
Kreitler S 69
Krishnasamy S 591
Kristjansen PEG 157, 579
Kührer I 161
Kusumanto YH 791
Kutz K S3: 15

L
La Vecchia C 41, 289
Lacave AJ 794
Ladenstein R S1: 45
Lalisang F 426
Langenberg CJM S3: 47
Latini P 847
Lauria F 575
le Maignan C 635
Leach MO 597
Leahy M 385, 703
Leclercq B 679
Lehnert M 11
Leitgeb C 161
Leonard RCF 257, 853
Lepage E 651, S1: 7
Levi F 289
Levi J 741
Levin L S4: 23, S4: 49, S4: 83
Levine AM 621
Levy R 635
Lianes P 147
Liberati A 133
Liehn J-C 307
Lietti G 37, 892
Lim J 385
Lind M 377, S4: 57
Lippman M 195
Lister TA 63, 385, 703, 802
Litos A 896
Ljubimova NV 663
Loboguerrero A 307
Lohmann R 695
Lombardi F 831, 889
Lombardo L 245
Lopez M 689
Lotz BP 567
Lotz J-P S2: 29
Louloudaki D 256
Löwenberg B S1: 59, S1: 81
Lucchini V 151, 775
Ludwig ChU 825
Ludwig H 161
Lüer M 520
Luisi A 213
Lund B 169, 264, 673, S4: 1, S4: 23, S4: 35, S4: 49, S4: 83
Luthra R 51
Luzi Fedeli S 83
Lydon APM 325

M
Machover D S2: 29
Maestu Maiques I 896
Magni M 759, 889
Magnius L 229
Mahjoubi M 333
Mainini F 133
Maiolo AT 521
Maksymiuk AW 141
Mallafré J 313
Malta Corea A 37, 892
Mangioni C 517, 775
Mansi JL 433, 597
Mantovani A 35
Mao J-H 853
Maranzano E 847
Marcellini M 689
Mari E 133
Marini G S2: 41
Marpicati P S2: 41
Marquet J S2: 29
Martinelli G 553
Martínez-Maza O S4: 3
Martoni A S2: 45
Marzola M 517, 775
Masera G 37, 892
Massazza G 151
Massutí B 753
Mastore M 213
Mauban S S2: 29
Mayordomo JI 432
Mazzaferro V 489
McCallum P 63
McClay E 221
McCready VR 597
McLaughlin P 125, 205
McLeay GF 509
McMillan AK S1: 21
McNicol AM 499
McVie JG 465, 804
Meacci M 847
Mead GM 857
Melotti B S2: 45
Menard S 775
Mendiola C 147
Mendoza Solórzano L 313
Meriggi F S2: 41
Mermillod B 559
Merrouche Y 471
Mertens WC 331
Mescheryakov AA 663
Metz K 585
Metzger G S2: 29
Metzger U 735
Mick R 591
Mihich E 545
Miles D 409
Minotti V 847
Mironova GT 663
Mitrou PS 371
Mittra I 283
Molchanov GV 663
Molins Palau C 896
Monfardini S 85, 669
Montalar Salcedo J 896
Montini E S2: 41
Moore M 331
Morali F 775
Morassut S 669
Morel P 651
Morgenstern GR 417
Morittu L 409
Morizet J 679
Morritti MG S2: 45
Mossetti C 429
Mouratidou DK 896
Mouridsen HT 861
Mross K 45
Muggia FM 723
Muldal A 331
Müller U 399
Munárriz Gandia B 896

Munsell MF 125
Murphy D 377
Murray AMB 499
Mygind T 173

N
Namer M 195
Natalini G 701
Negri E 41
Neijt JP 349, 607, S4: 1, S4: 31, S4: 57, S4: 63, S4: 83
Nelli P 251, 489
Nicoletti MI 151
Nicolucci A 133
Nielsen D 861
Nielsen H 173
Nolè F 251, 489
Norder H 229
Nordlinger B S2: 21
Norton AJ 63

O
O'Grady P 481
Oakley C 433
Obrist R 475
Ocampo Hernandez E 37
Ojasoo T 195
Ore L 96
Oriana S 55
Osoba D 520
Otte C 585
Oza AM 385, 703
Ozols RF 663, S4: 49, S4: 57, S4: 83

P
Paaske Hansen O 169
Pacheco Espinoza C 37, 892
Paci E 9
Pagani O 517, 553
Paillot B 426
Pampallona S 735
Pannuti F S2: 45
Pansadoro V 241
Paoletti G 689
Pappagallo GL 657
Parazzini F 41
Parc R S2: 29
Paridaens R S3: 43
Parker I S3: 25
Passas J 147
Pastor Borgoñón M 8[illegible]o
Pastorino U 117
Patel N 515
Patel U 377
Pater J 520
Payne GS 597
Paz-Ares L 147
Peccatori F 759, 889
Pectasides D 256
Peltier P 307
Penna A 133
Perevodchikova NI 663
Perren T 515
Peters GJ 277, 317
Peterse JL 791
Philip T S1: iv, S1: 7
Piccart MJ 199, S4: 49, S4: 63, S4: 83
Piedbois P S2: 15
Piga A 717
Pignon JP 333
Pinedo HM 317, 321, 351
Pinkerton CR S1: 45
Pion JM 174
Piquet D 475
Pirgach N S3: 35
Pirovano C 55
Pittman K 515
Pitts JF 337
Planting ASTh 673, 789
Plaxe S 221
Poliwoda H 520
Pollera CF 701
Potgieter HC 567
Prendiville J 377
Prescott RJ 853
Primrose J 515
Pringle J 409
Prové AM 610, 883
Pugh W 51

Q
Queisser W 45
Quirt IC 254, 695
Quistorff B 157

R
Rørth M 485
Raats JI 567
Radford JA 417, 877
Räisänen I S3: 31
Randimbison L 289
Rankin EM 337
Ranson M 377
Raphael M 635
Rapoport BL 567
Rapoport Y 69
Raspadori D 575
Ratain MJ 591
Ravagnani F 759
Redaelli L 775
Redman JR 205
Reiner A 643
Renard J 303
Renninson J 377
Reyes F 651, S1: 7
Reynders M 643
Ribrag V 679
Richaud J S2: 29
Richel DJ 791
Rinaldi M 689
Ripamonti C 15, 187, 267
Rivera F 147, 432
Rocca A 831
Rochefort H 195
Rodenhuis S 81, 785, 791
Rodriguez MA 125, 205
Roelofs EJM 426
Rohatiner AZS 63, 385, 802
Roila F 701, 795
Roithmann S 635
Romaguera JE 51, 205
Roncari A 429
Rondelli D 575
Rosselli Del Turco M 9
Rosing H 673
Rossi A 802
Rossi B 15
Rota Scalabrini D 245
Rotzén M 229
Rougier Ph 333, S2: 21
Roulston JE 257
Rovelli A 892
Rubens RD 712
Rubio C 229
Rüfenacht E S3: 25
Russo D 575
Rustin GJS S4: 3, S4: 71, S4: 83
Rustum YM 277
Rutgers EJT 791
Ruzicka J 289

S
Sabbatani S 85
Sabbioni MEE 714
Sagaster P 161
Sahmoud T 607
Saita L 187, 267
Salmon R S2: 29
Salvagno L 657
Salzer H 697
Sanchez-Hernández JJ 753
Santoro A 359, 831
Santucci A 847
Sbanotto A 187, 267
Schaake-Koning CCE 791
Schemper M 643
Scheulen ME 585
Schiøler V 861
Schilsky RL 591
Schmidt M S3: 31
Schmoll H-J 520
Schornagel JH 791
Schouten HC 75, 295
Schouten L 295
Schrijvers D 610, 883
Schutte B 643
Scorpiglione N 133
Sebban C 651
Seeber S 585
Segarra A 313
Selby P 515
Senn HJ 735
Sessa C 37, 517, 553, 892, S4: 35, S4: 63, S4: 83
Sevelda P 697
Sezeur A S2: 29
Shipman R 825
Shore T 695
Siena S 759, 889

Silva Espinoza F 37
Silver H 695
Silvestrini R 213
Simoncini E S2: 41
Sinicco A 85
Skinnider LF 141
Sklenar I 759
Skov Hansen M 579
Skovsgaard T 861
Slevin ML 515, 529
Smeets J 295
Smith A 433
Smith IE 877
Smyth JF 101, 303, 533
Snow GB 785
Snyder R 741
Soedirman JR 403
Soelberg Sørensen P 579
Sokolov AV 663
Solá C 313
Solé M 313
Sölétormos G 861
Somers R 839
Sorarù M 657
Sorbe B S3: 31, S3: 39
Sorio R 669
Souhami RL 325, 409, S1: 29
Soutter WP S4: 83
Spang-Thomsen M 157
Spatti GB 55
Spina M 85
Spitzer G 767
Stadler W 451
Stahel RA 399
Stansfeld AG 385
Steger G 643
Sternberg CN 241, 403
Steward WP 509
Stewart D 331
Stockler M 549
Stockmeyer M S3: 31
Stoll BA 121
Stoter G 789
Swan F Jr 125, 205
Sweetenham JW 63, 857

T

Taal BG 81, 607, 839
Tagliabue E 775
Taillan B 635
Tattersall MHN 23, 103, 549
Taylor S 205
Tedeschi M 55
ten Bokkel Huinink WW 81, S4: 41, S4: 83
Terrier-Lacombe M-J 871
Thatcher N 23, 103, 877
Théodore C 793, 871
Thigpen JT S4: 35, S4: 49, S4: 63, S4: 83
Tilly H 651, S1: 7
Tindall VR 377
Tirelli U 85
Tjean M S3: 43
Tjulandin SA 663
Tobias JS 283
Tobler A 339
Tognoni G 7
Tomiak E 199
Tonato M 847
Tondini C 831
Torri V 553
Tourani JM 635
Trent JM 821
Tres A 753
Tropé C S4: 3, S4: 83
Tura S 575

U

Umek H 161
Uziely B 723

V

Vaccher E 85
Valagussa P 94, 359, 831, 889
Valdimarsdottir H 745
van Asche C 643
van der Burg MEL S4: 17, S4: 71, S4: 83
van der Gaast A 789
van der Wall E 791
van Groeningen CJ 317
van Heerde P 839
van Hoef MEHM 877
van Houwelingen HC S4: 79, S4: 83
van Oosterom AT 403, 610, 883
Van Belle S S3: 43
Varini M 735
Varthalitis I 256
Vavra N 697
Veenhof CHN 607
Velasquez WS 125, 205
Venema-Gaberscek E 321
Venner P 331
Ventafridda V 15, 187, 267
Verity L 475
Verma S 254
Vermorken JB 303, 785, S4: 41, S4: 83
Verweij J 673, 785, 789
Vici P 689
Villar-Grimalt A 753
Vineis P 245
Viñolas N 313
Vischer MW 339
Vogelzang NJ 451
Vokes EE 591
Volovics L 295
Vonck I 610
Vose JM 767, S1: 1
Vuillez J-P 307

W

Wagener DJTh 426
Wainer IW S2: 7
Wanders J 610
Ward U 515
Wastnage R 433
Weber T 475
Weichselbaum RR 591
Weissler K 69
White JM 853
Whitehouse JMA 857
Whitman G 591
Wielgosz G 693, 695
Wijnen JTh 75
Wils J 295, 426
Winkel P 861
Woll PJ 877
Wong D 331
Workman P 466
Wrigley PFM 385
Wuillemin WA 339

Y

Young VJ 254

Z

Zaja F 575
Zambetti M 895
Zaniboni A S2: 41
Zarba JJ 333
Zaridze D 495
Zecca E 187, 267
Zeuli M 241
Zimmerman SO 125
Zinzani PL 575
Zittoun J S2: 1, S2: 29
Zola P 133
Zomers PJW S3: 47
Zucchetti M 517, 553, 895
Zulian GB 559
Zunino F 55